We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Yin and Yang M&A

5 October 2020 By Robert Cyran

The $132 bln drugmaker’s Celgene mega-deal last year left it dependent on cancer treatments and vulnerable to generic competition and the whims of governments. Paying $13 bln for revenue-free MyoKardia offers some political and patent protection – but it costs an arm and a leg.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)